ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS
Chronic myelogenous leukemia (CML) is characterized by a translocation between the long arms of chromosomes 9 and 22 (Philadelphia chromosome or Ph; it was named after the city where it was first identified). At the molecular level, the translocation (gene rearrangement) results in fusion of BCR gene coding sequences to ABL gene coding sequences. The resultant chimeric gene and fusion transcript encode a fusion protein with constitutively activated tyrosine kinase activity, which leads to cell growth and proliferation responsible for the development of certain leukemias. Approximately 95% of cases of chronic myelogenous leukemia (CML, including CML in blast crisis) have the characteristic t(9;22)(q34;q11). The remaining cases either have a cryptic translocation between 9q34 and 22q11 that cannot be identified by routine cytogenetic analysis, or have variant translocations involving a third or even a fourth chromosome besides 9 and 22. A subset of acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) also have the Ph chromosome, and therefore are positive for bcr/abl, t(9;22) translocation.
Imatinib is considered front line treatment in patients with CML. Imatinib selectively targets and inhibits the fusion protein that results from this particular translocation. Imatinib resistance can occur during treatment, resulting in primary or secondary resistance. Both BCR-ABL dependent and independent mechanisms have been identified as causes of imatinib resistance. The absence/presence of an ABL kinase domain mutation helps determine alternative treatments such as: increase in imatinib dosage, utilization of second generation kinase inhibitors (dasatinib, nilotinib), evaluation of allogeneic stem cell transplant, and investigational protocol testing.
- Hematologic or cytogenetic resistance to imatinib in patients with CML
- Prior to initiation of alternative kinase inhibitor therapy (dasatinib, nilotinib)
- Determination of IC50 value of treatment concentration
- Hematologic or cytogenetic relapse in CML patients previously treated with imatinib
- Evaluation of significantly rising levels of quantitative BCR-ABL
- Interval testing for patients treated with second generation kinase inhibitors
- Can also be utilized for patients presenting with accelerated phase or blast crisis at imatinib initiation
- ABL Kinase Domain Mutations are reported as positive, negative, or not amplified. Positive test results are reported with specific mutation.
- It is critical that there be sufficient BCR-ABL in a specimen for amplification. If insufficient BCR-ABL is present, it will be reported as “not amplified.” This result does not exclude the presence of a BCR/ABL mutation.
- Variable levels of drug resistance have been observed for different mutations, influencing patient prognosis.
- Most labs do not test for every known mutation so that a negative result does not completely exclude the possibility of a mutation.
Positive results are found in:
- Chronic myelogenous leukemia
- Subsets of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
Mutation not detected (Negative for abl mutations)
Peripheral blood or bone marrow collected in lavender top (EDTA) tube or yellow top (ACD-A) tube.
Transfer blood and bone marrow at ambient within 24 hours.
Store refrigerated for 7 days.
- Blood. 2011 Aug 4;118(5):1208-15. [PMID: 21562040]
- J Clin Oncol. 2009 Dec 10;27(35):6041-51. [PMID: 19884523]
- Blood. 2007 Dec 1;110(12):4005-11. [PMID: 17785585]
- Expert Rev Anticancer Ther. 2008 Sep;8(9):1387-98. [PMID: 18759691]
- Blood. 2007 Oct 1;110(7):2242-9. [PMID: 17496200]
- J Mol Diagn. 2009 Jan;11(1):4-11. [PMID: 19095773]